StockpollyBeta
Get App
Popularity #1,524
CADL · NASDAQ · Biotechnology

Candel Therapeutics (CADL)

Develops viral immunotherapies for solid tumors through adenovirus and HSV platforms.

$11.58
vs last close−0.27 (−2.28%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
910899881113161627
Research & development674555478111020
334433445567
General & administrative334433445567
Operating income−9−10−8−9−9−8−8−11−13−16−16−27
0−10−14−2−61662−147−12
Interest income100000111112
Interest expense111100000122
Other non-operating income−1001316−16−7−212−911
Income before tax−8−11−8−22−11−147−5−11−29−9−39
Net income from continuing operations−8−11−8−22−11−147−5−11−29−9−39
Net income−8−11−8−22−11−147−5−11−29−9−39
EPS, basic−$0.29−$0.38−$0.28−$0.74−$0.33−$0.40$0.23−$0.09−$0.21−$0.54−$0.14−$0.52
EPS, diluted−$0.29−$0.38−$0.28−$0.74−$0.33−$0.40$0.23−$0.09−$0.21−$0.54−$0.14−$0.52
Weighted average shares, basic292929303236325155556274
Weighted average shares, diluted292929303236325155556274
EBITDA−8−10−7−21−10−138−4−11−28−7−37
Depreciation & amortization000000000000
EBIT−8−10−8−22−10−148−5−11−28−7−37